The manufacturer has managed to place itsĮntire portfolio of second-hand aircraft. Is highlighted through this HOA, as well as through the fact that Latest market forecast, its first since 2018, shows strong demandĪcross the world for turboprops over the next 20 years. Turboprops, our strong links with ATR will prove invaluable.” As we are looking to expand and become the go-to lessor of With the most modern, profitable and sustainable aircraft on the This new deal is further proof of our commitment toĬreate growth and value for regional operators, providing them Today and tomorrow and this is why we are investing in the ATR Said, “We firmly believe that turboprops are the technology of I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Steve Gorman, Chief Executive Officer of Abelo, I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. IRB of Boston Children's Hospital gave ethical approval for this work. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Hood Foundation Grant (YP), and NIH K08 CA222684 (YP). Baldrick's Foundation Consortium grant (YP), Charles H. The authors have declared no competing interest. These findings support the use of aberrant isoform analysis in targeted RNA sequencing data as a robust strategy for the detection of clinically significant DNA events. ![]() ![]() To demonstrate utility in other tumor types, outlier analysis was 100% (9/9) sensitive and 100% (255/255) specific for KMT2A-PTD in hematologic samples and 100% (7/7) sensitive and 100% (79/79) specific for FGFR1 tyrosine kinase domain duplication in brain tumors. Outlier analysis also identified putative PAX5amp cases and revealed partial tandem duplication (PTD) spanning IKZF1 N159Y in the B-ALL with mutated N159Y subtype. ![]() ![]() Outlier analysis of known and novel IKZF1, ERG, and PAX5 isoforms was 97.0% (32/33), 90% (9/10), and 100% (6/6) sensitive and 97.8% (226/231), 100% (35/35), and 88.5% (23/26) specific for IKZF1 intragenic or 3’ deletions, DUX4r, and PAX5 intragenic deletions respectively, where false positives were favored to represent low-level deletions below the limit of DNA-based detection. In this study, we screened for outlier expression of isoforms within targeted RNA sequencing assays designed for fusions. The high-risk IKZF1 plus signature depends on gene deletions including PAX5 while intragenic PAX5 amplifications (PAX5amp) are recurrent in the provisional B-ALL with PAX5-alteration subtype. Aberrant ERG isoforms have been proposed as markers of the favorable-risk DUX4-rearranged ( DUX4r) subtype while deletion-mediated IKZF1 isoforms are associated with adverse prognosis in non- DUX4r B-ALL. Recognition of aberrant gene isoforms indicative of underlying DNA events can impact molecular classification and risk stratification of B lymphoblastic leukemia (B-ALL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |